GILEAD
Creating Possible

Advanced Notification of Product Discontinuation

Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) film-coated tablets currently indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months

Due to low utilisation of Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg; EFV/FTC/TDF) Gilead Sciences, Inc. has made the decision to discontinue Atripla® in the United Kingdom, effective as of 17th December 2021, as agreed with the Department of Health and Social Care (DHSC). Stock is expected to be exhausted by February 2022.

The decision to discontinue Atripla® is not the result of any ongoing or new safety issues with Atripla®. We have assessed the impact of the discontinuation of Atripla® both on clinical centres and people living with HIV. We know for some of those patients this may be a cause for concern, however Gilead Sciences believes that the discontinuation of Atripla® will not create any unmet need for HIV-1 treatment, due to the availability of generic alternatives and several other licensed and guideline recommended antiretroviral agents with indications that could make them suitable alternatives for patients currently prescribed Atripla®.

Following the discontinuation of Atripla®, physicians can continue to prescribe generic EFV/FTC/TDx or clinically appropriate alternatives that are licensed and available in the United Kingdom for the treatment of people living with HIV-1.

Gilead Sciences is communicating this advanced notification to ensure appropriate therapeutic follow-up for people living with HIV that are currently treated with Atripla®, and to ensure any resources your organisation may have relating to Atripla are updated.

Should you have any questions or if you would like any further information, please contact your Gilead Public Affairs contact (Rebecca.dandridge@gilead.com) or UKCustomer.Services@gilead.com

Date of preparation: May 2021
Document Number: UK-ATR-0005